Guidelines on “Similar Biologics: Regulatory requirements for Market Authorization in India” will be implemented from 15th September 2012.
The “Guidelines on Similar Biologics” prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a similar biologic claiming to be similar to an already authorized reference biologic.
The guidelines address the regulatory pathway regarding manufacturing process and quality aspects for similar biologics.
These guidelines also address the pre-market regulatory requirements including comparability exercise for quality, preclinical and clinical studies and post market regulatory requirements for similar biologics.
For further details visit
https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTU0NA==
Recent Posts
Preparing for CDSCO Inspection: Documentation, Site Readiness, and Common Reasons for Delay
A CDSCO inspection is one of the most consequential events in a Medical Device company’s regulatory journey in India. Whether you are a manufacturer or Importer, demonstrating compliance with th..
Stem Cell Regulation in India: Separating Legitimate Therapy Development from Regulatory Risk
Introduction Stem cell therapy represents one of the most scientifically promising and regulatorily complex frontiers in modern medicine. India’s stem cell regulatory landscape presents both gen..
Cosmetic Labelling in India: CDSCO, , and Legal Metrology — Three Bodies, One Label
Three Regulatory Bodies, One Physical Label A Cosmetic label entering India is reviewed — directly or through market surveillance — against the requirements of three separate regulatory frameworks..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore